{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T10:25:29Z","timestamp":1792405529449,"version":"4.4.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,6,19]],"date-time":"2019-06-19T00:00:00Z","timestamp":1560902400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,6,19]],"date-time":"2019-06-19T00:00:00Z","timestamp":1560902400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Neoantigens (nAgs) are promising tumor antigens for cancer vaccination with the potential of inducing robust and selective T cell responses. Genetic vaccines based on Adenoviruses derived from non-human Great Apes (GAd) elicit strong and effective T cell-mediated immunity in humans. Here, we investigate for the first time the potency and efficacy of a novel GAd encoding multiple neoantigens. Prophylactic or early therapeutic vaccination with GAd efficiently control tumor growth in mice. In contrast, combination of the vaccine with checkpoint inhibitors is required to eradicate large tumors. Gene expression profile of tumors in regression shows abundance of activated tumor infiltrating T cells with a more diversified TCR repertoire in animals treated with GAd and anti-PD1 compared to anti-PD1. Data suggest that effectiveness of vaccination in the presence of high tumor burden correlates with the breadth of nAgs-specific T cells and requires concomitant reversal of tumor suppression by checkpoint blockade.<\/jats:p>","DOI":"10.1038\/s41467-019-10594-2","type":"journal-article","created":{"date-parts":[[2019,6,19]],"date-time":"2019-06-19T12:04:56Z","timestamp":1560945896000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":93,"title":["Adenoviral vaccine targeting multiple neoantigens as strategy to eradicate large tumors combined with checkpoint blockade"],"prefix":"10.1038","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0763-6269","authenticated-orcid":false,"given":"Anna Morena","family":"D\u2019Alise","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0502-1962","authenticated-orcid":false,"given":"Guido","family":"Leoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella","family":"Cotugno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fulvia","family":"Troise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Langone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imma","family":"Fichera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"De Lucia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lidia","family":"Avalle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"Vitale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriano","family":"Leuzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Bignone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Di Matteo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio Giovanni","family":"Tucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3739-3966","authenticated-orcid":false,"given":"Valeria","family":"Poli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armin","family":"Lahm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Teresa","family":"Catanese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Folgori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Colloca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo","family":"Nicosia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Scarselli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,6,19]]},"reference":[{"key":"10594_CR1","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1158\/2326-6066.CIR-13-0022","volume":"1","author":"N Hacohen","year":"2013","unstructured":"Hacohen, N., Fritsch, E. F., Carter, T. A., Lander, E. S. & Wu, C. J. Getting personal with neoantigen-based therapeutic cancer vaccines. Cancer Immunol. Res 1, 11\u201315 (2013).","journal-title":"Cancer Immunol. Res"},{"key":"10594_CR2","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/ni.3682","volume":"18","author":"E Tran","year":"2017","unstructured":"Tran, E., Robbins, P. F. & Rosenberg, S. A. \u2018Final common pathway\u2019 of human cancer immunotherapy: targeting random somatic mutations. Nat. Immunol. 18, 255\u2013262 (2017).","journal-title":"Nat. Immunol."},{"key":"10594_CR3","doi-asserted-by":"publisher","first-page":"2500","DOI":"10.1056\/NEJMc1713444","volume":"377","author":"M Yarchoan","year":"2017","unstructured":"Yarchoan, M., Hopkins, A. & Jaffee, E. M. Tumor mutational burden and response rate to PD-1 inhibition. N. Engl. J. Med. 377, 2500\u20132501 (2017).","journal-title":"N. Engl. J. Med."},{"key":"10594_CR4","doi-asserted-by":"crossref","unstructured":"Rizvi, N. A. et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348, 124\u2013128 (2015).","DOI":"10.1126\/science.aaa1348"},{"key":"10594_CR5","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1038\/nature14001","volume":"515","author":"M Yadav","year":"2014","unstructured":"Yadav, M. et al. Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing. Nature 515, 572\u2013576 (2014).","journal-title":"Nature"},{"key":"10594_CR6","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/nature13988","volume":"515","author":"MM Gubin","year":"2014","unstructured":"Gubin, M. M. et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature 515, 577\u2013581 (2014).","journal-title":"Nature"},{"key":"10594_CR7","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1038\/nature14426","volume":"520","author":"S Kreiter","year":"2015","unstructured":"Kreiter, S. et al. Mutant MHC class II epitopes drive therapeutic immune responses to cancer. Nature 520, 692\u2013696 (2015).","journal-title":"Nature"},{"key":"10594_CR8","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1126\/science.aaa3828","volume":"348","author":"BM Carreno","year":"2015","unstructured":"Carreno, B. M. et al. Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells. Science 348, 803\u2013808 (2015).","journal-title":"Science"},{"key":"10594_CR9","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/nature22991","volume":"547","author":"PA Ott","year":"2017","unstructured":"Ott, P. A. et al. An immunogenic personal neoantigen vaccine for patients with melanoma. Nature 547, 217\u2013221 (2017).","journal-title":"Nature"},{"key":"10594_CR10","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/nature23003","volume":"547","author":"U Sahin","year":"2017","unstructured":"Sahin, U. et al. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature 547, 222\u2013226 (2017).","journal-title":"Nature"},{"key":"10594_CR11","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"Pardoll, D. M. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12, 252\u2013264 (2012).","journal-title":"Nat. Rev. Cancer"},{"key":"10594_CR12","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1126\/science.aaa8172","volume":"348","author":"P Sharma","year":"2015","unstructured":"Sharma, P. & Allison, J. P. The future of immune checkpoint therapy. Science 348, 56\u201361 (2015).","journal-title":"Science"},{"key":"10594_CR13","doi-asserted-by":"publisher","first-page":"561","DOI":"10.3389\/fphar.2017.00561","volume":"8","author":"HO Alsaab","year":"2017","unstructured":"Alsaab, H. O. et al. PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome. Front Pharm. 8, 561 (2017).","journal-title":"Front Pharm."},{"key":"10594_CR14","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","volume":"366","author":"SL Topalian","year":"2012","unstructured":"Topalian, S. L. et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366, 2443\u20132454 (2012).","journal-title":"N. Engl. J. Med."},{"key":"10594_CR15","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","volume":"387","author":"RS Herbst","year":"2016","unstructured":"Herbst, R. S. et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 387, 1540\u20131550 (2016).","journal-title":"Lancet"},{"key":"10594_CR16","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert, C. et al. Pembrolizumab versus Ipilimumab in advanced melanoma. N. Engl. J. Med. 372, 2521\u20132532 (2015).","journal-title":"N. Engl. J. Med."},{"key":"10594_CR17","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","volume":"387","author":"JE Rosenberg","year":"2016","unstructured":"Rosenberg, J. E. et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 387, 1909\u20131920 (2016).","journal-title":"Lancet"},{"key":"10594_CR18","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","volume":"168","author":"P Sharma","year":"2017","unstructured":"Sharma, P., Hu-Lieskovan, S., Wargo, J. A. & Ribas, A. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell 168, 707\u2013723 (2017).","journal-title":"Cell"},{"key":"10594_CR19","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1586\/erv.13.15","volume":"12","author":"S Capone","year":"2013","unstructured":"Capone, S. et al. Development of chimpanzee adenoviruses as vaccine vectors: challenges and successes emerging from clinical trials. Expert Rev. Vaccines 12, 379\u2013393 (2013).","journal-title":"Expert Rev. Vaccines"},{"key":"10594_CR20","doi-asserted-by":"publisher","first-page":"115ra111","DOI":"10.1126\/scitranslmed.3003155","volume":"4","author":"E Barnes","year":"2012","unstructured":"Barnes, E. et al. Novel adenovirus-based vaccines induce broad and sustained T-cell responses to HCV in man. Sci. Transl. Med. 4, 115ra111 (2012).","journal-title":"Sci. Transl. Med."},{"key":"10594_CR21","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1093\/infdis\/jir850","volume":"205","author":"GA O\u2019Hara","year":"2012","unstructured":"O\u2019Hara, G. A. et al. Clinical assessment of a recombinant simian adenovirus ChAd63: a potent new vaccine vector. J. Infect. Dis. 205, 772\u2013781 (2012).","journal-title":"J. Infect. Dis."},{"key":"10594_CR22","doi-asserted-by":"publisher","first-page":"2355","DOI":"10.1038\/mt.2012.223","volume":"20","author":"SH Sheehy","year":"2012","unstructured":"Sheehy, S. H. et al. ChAd63-MVA-vectored blood-stage malaria vaccines targeting MSP1 and AMA1: assessment of efficacy against mosquito bite challenge in humans. Mol. Ther. 20, 2355\u20132368 (2012).","journal-title":"Mol. Ther."},{"key":"10594_CR23","doi-asserted-by":"publisher","first-page":"261ra153","DOI":"10.1126\/scitranslmed.3009185","volume":"6","author":"L Swadling","year":"2014","unstructured":"Swadling, L. et al. A human vaccine strategy based on chimpanzee adenoviral and MVA vectors that primes, boosts, and sustains functional HCV-specific T-cell memory. Sci. Transl. Med. 6, 261ra153 (2014).","journal-title":"Sci. Transl. Med."},{"key":"10594_CR24","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1056\/NEJMoa1410863","volume":"376","author":"JE Ledgerwood","year":"2017","unstructured":"Ledgerwood, J. E. et al. Chimpanzee adenovirus vector Ebola Vaccine. N. Engl. J. Med. 376, 928\u2013938 (2017).","journal-title":"N. Engl. J. Med."},{"key":"10594_CR25","doi-asserted-by":"publisher","first-page":"300ra126","DOI":"10.1126\/scitranslmed.aac5745","volume":"7","author":"CA Green","year":"2015","unstructured":"Green, C. A. et al. Chimpanzee adenovirus- and MVA-vectored respiratory syncytial virus vaccine is safe and immunogenic in adults. Sci. Transl. Med. 7, 300ra126 (2015).","journal-title":"Sci. Transl. Med."},{"key":"10594_CR26","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1038\/mt.2013.248","volume":"22","author":"N Borthwick","year":"2014","unstructured":"Borthwick, N. et al. Vaccine-elicited human T cells recognizing conserved protein regions inhibit HIV-1. Mol. Ther. 22, 464\u2013475 (2014).","journal-title":"Mol. Ther."},{"key":"10594_CR27","doi-asserted-by":"publisher","first-page":"2930","DOI":"10.1172\/JCI91190","volume":"127","author":"M Ayers","year":"2017","unstructured":"Ayers, M. et al. IFN-gamma-related mRNA profile predicts clinical response to PD-1 blockade. J. Clin. Invest 127, 2930\u20132940 (2017).","journal-title":"J. Clin. Invest"},{"key":"10594_CR28","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s40425-018-0367-1","volume":"6","author":"P Danaher","year":"2018","unstructured":"Danaher, P. et al. Pan-cancer adaptive immune resistance as defined by the tumor inflammation signature (TIS): results from The Cancer Genome Atlas (TCGA). J. Immunother. Cancer 6, 63 (2018).","journal-title":"J. Immunother. Cancer"},{"key":"10594_CR29","doi-asserted-by":"publisher","first-page":"E7240","DOI":"10.1073\/pnas.1608555113","volume":"113","author":"S Wang","year":"2016","unstructured":"Wang, S. et al. Intratumoral injection of a CpG oligonucleotide reverts resistance to PD-1 blockade by expanding multifunctional CD8+ T cells. Proc. Natl. Acad. Sci. USA 113, E7240\u2013E7249 (2016).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10594_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2164-15-190","volume":"15","author":"JC Castle","year":"2014","unstructured":"Castle, J. C. et al. Immunomic, genomic and transcriptomic characterization of CT26 colorectal carcinoma. BMC Genomics 15, 190 (2014).","journal-title":"BMC Genomics"},{"key":"10594_CR31","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1007\/s00251-005-0798-y","volume":"57","author":"HH Bui","year":"2005","unstructured":"Bui, H. H. et al. Automated generation and evaluation of specific MHC binding predictive tools: ARB matrix applications. Immunogenetics 57, 304\u2013314 (2005).","journal-title":"Immunogenetics"},{"key":"10594_CR32","doi-asserted-by":"publisher","first-page":"9730","DOI":"10.1073\/pnas.93.18.9730","volume":"93","author":"AY Huang","year":"1996","unstructured":"Huang, A. Y. et al. The immunodominant major histocompatibility complex class I-restricted antigen of a murine colon tumor derives from an endogenous retroviral gene product. Proc. Natl. Acad. Sci. USA 93, 9730\u20139735 (1996).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10594_CR33","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1038\/nbt.3979","volume":"35","author":"DA Bolotin","year":"2017","unstructured":"Bolotin, D. A. et al. Antigen receptor repertoire profiling from RNA-seq data. Nat. Biotechnol. 35, 908\u2013911 (2017).","journal-title":"Nat. Biotechnol."},{"key":"10594_CR34","doi-asserted-by":"publisher","first-page":"e008748","DOI":"10.1136\/bmjopen-2015-008748","volume":"5","author":"CA Green","year":"2015","unstructured":"Green, C. A. et al. Safety and immunogenicity of novel respiratory syncytial virus (RSV) vaccines based on the RSV viral proteins F, N and M2-1 encoded by simian adenovirus (PanAd3-RSV) and MVA (MVA-RSV); protocol for an open-label, dose-escalation, single-centre, phase 1 clinical trial in healthy adults. BMJ Open 5, e008748 (2015).","journal-title":"BMJ Open"},{"key":"10594_CR35","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1158\/0008-5472.CAN-11-3722","volume":"72","author":"JC Castle","year":"2012","unstructured":"Castle, J. C. et al. Exploiting the mutanome for tumor vaccination. Cancer Res. 72, 1081\u20131091 (2012).","journal-title":"Cancer Res."},{"key":"10594_CR36","doi-asserted-by":"publisher","unstructured":"The problem with neoantigen prediction. Nat. Biotechnol. 35, 97 (2017). https:\/\/doi.org\/10.1038\/nbt.3800.","DOI":"10.1038\/nbt.3800"},{"key":"10594_CR37","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1038\/nature18300","volume":"534","author":"LM Kranz","year":"2016","unstructured":"Kranz, L. M. et al. Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy. Nature 534, 396\u2013401 (2016).","journal-title":"Nature"},{"key":"10594_CR38","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/j.cell.2017.09.028","volume":"171","author":"N Riaz","year":"2017","unstructured":"Riaz, N. et al. Tumor and microenvironment evolution during Immunotherapy with Nivolumab. Cell 171, 934\u2013949 e15 (2017).","journal-title":"Cell"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-019-10594-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-019-10594-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-019-10594-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T00:01:29Z","timestamp":1671235289000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-019-10594-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,19]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["10594"],"URL":"https:\/\/doi.org\/10.1038\/s41467-019-10594-2","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,19]]},"assertion":[{"value":"23 July 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.N., E.S., A.F., and S.C. are founders of Nouscom. All the other authors are employees of Nouscom, except V.P., L.A., A.L., declaring no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2688"}}